Skip to content
Screener

Vertex Pharmaceuticals VRTX Business Segments — General and administrative expenses

Similar metrics at other companies

TMH
TMHCCentral — General and administrative expenses
$8.51M+5.3%
TMH
TMHCEast — General and administrative expenses
$13.59M+13.3%
TMH
TMHCWest — General and administrative expenses
$11.62M-2.7%
National Health Investors logo
NHISHOP — General and administrative expenses
$0
National Health Investors logo
NHIInvestments — General and administrative expenses
$0
Texas Pacific Land logo
TPLLRM — General and administrative expenses
$5.25M+43.8%

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$122.89B+24.3%
Enterprise value$117.01B+22.6%
P/E27.9×
P/S9.8×+1.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%
Net margin35%
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Development expenses756.6773.6
Acquired in-process research and development expenses0.519.8
Selling and other commercial expenses313.6241.1
General and administrative expenses180.1155.3
Intangible asset impairment charge379.0
Interest income, net(114.8)(117.9)
Other segment items (1)0.219.8
Provision for income taxes221.584.1

Item 1. Financial Statements (unaudited)

FAQ

What is Vertex Pharmaceuticals's business segments — general and administrative expenses?
Vertex Pharmaceuticals (VRTX) reported business segments — general and administrative expenses of $180.1M in Q1 2026.
How has Vertex Pharmaceuticals's business segments — general and administrative expenses changed year-over-year?
Vertex Pharmaceuticals's business segments — general and administrative expenses increased by 16.0% year-over-year, from $155.3M to $180.1M.
What is the long-term trend for Vertex Pharmaceuticals's business segments — general and administrative expenses?
Over 3 years (2022 to 2025), Vertex Pharmaceuticals's business segments — general and administrative expenses has grown at a 11.0% compound annual growth rate (CAGR), from $475.8M to $650.3M.
What does business segments — general and administrative expenses mean?
Overhead costs associated with corporate functions such as legal, human resources, finance, and executive management. These represent the fixed costs of running the business operations.

Ask your AI about Vertex Pharmaceuticals's business segments — general and administrative expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude